News

Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phas


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid

 26/04/2016

Oxford, UK – Summit Therapeutics plc, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and 

In contrast to many current therapeutic approaches to DMD, utrophin modulation has the potential to treat all boys and young men with DMD, regardless of their underlying dystrophin gene mutation. 

“The IND clearance for PhaseOut DMD paves the way to expand PhaseOut DMD into the US and will provide access to a wider network of leading physicians in DMD as we seek to improve the lives of patients and families living with this devastating disease,” said Ralf Rosskamp, MD, Chief Medical Officer of Summit. “PhaseOut DMD aims to show the potential benefits of ezutromid as a disease modifying approach for DMD for the first time in patients, and this approach could ultimately benefit the entire DMD patient population.” 

Summit expects to begin enrolling patients into US sites in the third quarter of 2016.


CompanyOxford, UK - Summit Therapeutics plc
Company Websitehttp://www.summitplc.com/

© Catalyst Innovation Portal 2019